CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 91 enrolled
Drug / intervention
Fluoxetine +2 moredrug
Likely dose
Fluoxetine 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00533117
NCT00533117Phase 4Completed

Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder

New York State Psychiatric Institute·interventional·Posted Sep 21, 2007·Updated Jan 5, 2024

In Brief

A Phase 4 clinical trial evaluating Fluoxetine, Dialectical Behavior Therapy, and 1 other intervention for Borderline Personality Disorder. Completed, enrolled 91 participants across 1 site.

Detailed Summary

This study will determine whether dialectical behavior therapy and fluoxetine are more effective combined or alone in treating people with borderline personality disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 21, 2007
Enrollment StartMar 1, 2001
Primary CompletionJan 1, 2008
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 18.8 years ago

Interventions

Fluoxetinedrug

Fluoxetine is administered in standard dosing 20, 40, 60, 80 mg increased monthly if tolerated

Dialectical Behavior Therapybehavioral

Dialectical Behavior Therapy is a form of CBT originally developed to treat suicidal and self injuring individuals with borderline personality disorder. Treatment consists of 2 sessions/week: individual psychotherapy and skills training group.

Supportive psychotherapybehavioral

Supportive therapy is a manualized form of psychotherapy designed to enhance individual's strengths and coping mechanisms while reducing distress.